Video

Dr. Kris on the Use of Genetic Testing in Lung Cancer

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

Mark G. Kris, MD, Thoracic Oncology Service from Memorial Sloan-Kettering Cancer Center describes the use of genetic testing in lung cancer.

Dr. Kris says doctors have long known that despite a person having a diagnosis of a certain cancer, what happens to that person and their response to therapy varies quite a bit, and there has never been a good explanation as to why. In the last ten years, doctors have learned that, at least in lung cancer, the cancer cells are driven by genetic changes and mutations. When a specific mutation is discovered, it defines different groups of patients and gives the physician an idea of what therapy might be best.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.